<DOC>
	<DOCNO>NCT00193258</DOCNO>
	<brief_summary>This phase I/II trial evaluate bevacizumab/erlotinib combination addition imatinib ( Gleevec ) . The combined inhibition greatly enhance anti-tumor effect . Although safety bevacizumab/erlotinib/imatinib combination yet demonstrate , mild moderate side effect agent predict cause prohibitive toxicity . A brief phase I portion include trial , optimize dos 3 agent prior proceed phase II trial .</brief_summary>
	<brief_title>Bevacizumab , Erlotinib , Imatinib Treatment Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Bevacizumab + Erlotinib + Imatinib A brief phase I dose escalation study perform define imatinib dose use .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic unresectable clear cell renal carcinoma confirm biopsy Previous nephrectomy require Maximum 1 previous systemic regimen metastatic disease . Able perform activity daily live minimal assistance Measurable disease Adequate bone marrow , liver kidney Written informed consent . Age &lt; 18 year Treatment 1 previous systemic regimen History heart attack within 6 month Clinically significant cardiovascular disease Moderate severe vascular disease . Active brain metastasis . History evidence physical examination brain tumor Seizures control standard medical therapy history stroke serious disorder nervous system Clinical history cough vomit blood within past 3 month . PEG tubes G tube Chronic therapy NSAIDS platelet inhibitor Proteinuria Nonhealing wound , ulcer , long bone fracture Clinical evidence history bleed disorder Requiring full dose anticoagulation coumadin Receiving chronic steroid therapy Significant medical condition . Tumors clear cell History stroke within 6 month . History abdominal fistula , perforation , abscess within 6 month . Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Recurrent clear cell renal cell carcinoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Imatinib</keyword>
</DOC>